August 5, 2026

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Investor / Analysts Presentation

Please refer to our letter dated July 29, 2026, wherein we intimated the schedule of Investors/ Analysts call on August 6, 2026. In this connection, we enclose herewith the presentation that would be used in the said Investors / Analysts call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2026. The presentation is also being uploaded to the following weblink of the Company.

https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 19:53:24 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above.

Aurobindo Pharma Limited

Earnings Presentation

Q1FY27

Disclaimer

This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any part hereof, form the basis of, or be relied on in connection with, any contract, therefore.

This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance.

While these forward-looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, regulatory and legislative developments, and other key factors that we have indicated could adversely affect our business and financial performance.

Aurobindo Pharma Limited undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances.

This document is strictly confidential and may not be disclosed, reproduced or redistributed, in whole or in part, to any other person.

Table of Content

Q1FY27 Business & Financial Highlights

Key Financial Highlights of the Quarter

	Revenue	EBITDA	Net Profit
Q1FY27	₹ 9,150 Cr	₹ 1,924 Cr*	₹ 1,032 Cr
Q1FY26	₹ 7,868 Cr	₹ 1,603 Cr	₹ 824 Cr
Y-o-Y growth %	16.3%	20.0%	25.2%

*Operating EBITDA excluding one time impact of ₹43 Cr on account of derecognition of lease receivable (Refer Note-11 of Un-audited Consol Results)

Business Highlights – Q1FY27

- Revenue of ₹9,150 Cr with 16.3% growth Y-o-Y, driven by strong performance across all business areas, U.S. base business continued to grow driven by volume gains and new launches
- Operating EBITDA stood at ₹1,924 Cr with a margin of 21.0%
- Net Capex of US$ 78 million* primarily towards capability enhancements, new business developments
- Generated free cash flow of US$ 98mn during the quarter, with a strong net cash position (including investments) of ~US$ 42 million* as on 30-Jun-26, after payment of cash for Lannett acquisition of US$ 247 million and buyback of US$ 85 million
- Received final approval for 10 products and launched 10 products in the US market

*converted at USD:INR rate as on Jun 30th, 2026

Quarterly Performance – Q1FY27

Revenue (₹ Cr.)



EBITDA (₹ Cr.)



PAT (₹ Cr.)



Cash flows before dividend and buyback (US$ Mn)



*Operating EBITDA

Consolidated Business Performance

₹ Cr	Q1FY27	Q1FY26	Y-o-Y (%)	Q4FY26	Q-o-Q (%)
USA	3,770	3,488	8.1%	3,543	6.4%
Europe	2,937	2,338	25.6%	2,795	5.1%
Growth Markets*	1,063	772	37.7%	980	8.5%
ARV	330	355	-6.9%	328	0.8%
Total Formulations	**8,101**	**6,953**	**16.5%**	**7,646**	**6.0%**
Beta-lactam	800	636	25.7%	918	-12.9%
Non Beta-lactam	250	279	-10.6%	290	-13.8%
Total API	**1,049**	**916**	**14.6%**	**1,208**	**-13.1%**
Revenue from operations	**9,150**	**7,868**	**16.3%**	**8,853**	**3.4%**

*includes domestic sales of ₹ 104 Cr in Q1 FY27 against ₹ 75 Cr in Q4 FY26

US Formulations Business Performance Highlights

Revenue ex-gRevlimid (US$ Mn)



Commentary

- US revenue in Q1FY27 accounted for 41.2% of consolidated revenue. Ex-gRevlimid the revenue grew by 5% Q-o-Q. The growth was driven by strong volume gains coupled with new launches during the quarter
- The company has launched 10 products during the quarter
- Received final approval for 10 products during the quarter

Revenue Break-up by Business

Europe (EUR Mn)



Europe business posted growth of 11% Y-o-Y with strong performance across all key markets continuing its momentum

Growth Markets (US$ Mn)



Growth Markets reported Y-o-Y growth of 25% driven by strong performance across the markets

ARV (US$ Mn)



ARV business revenue remained broadly stable at INR 330 Cr with Q-o-Q variation driven by tender opportunities, accounting for 3.6% of consolidated revenue

API (₹ Cr.)



API revenues increased 14.6% Y-o-Y. Sequential performance reflected seasonal softness in the antibiotics portfolio

Financial Summary



Summary Consolidated Profit & Loss Statement

₹ Cr.	Q1FY27	Q1FY26	Y-o-Y Chg. (%)	Q4FY26	Q-o-Q Chg. (%)
Revenue from Operations	**9,150**	**7,868**	**16.3%**	**8,853**	**3.4%**
Gross Profit	**5,523**	**4,629**	**19.3%**	**5,424**	**1.8%**
Gross Margin	60.4%	58.8%	153 bps	61.3%	-91 bps
Overheads	-3,599	-3,025	18.9%	-3,623	-0.6%
Operating EBITDA (before Forex and Other Income)	**1,924**	**1,603**	**20.0%**	**1,801**	**6.8%**
EBITDA Margin	***21.0%***	***20.4%***	***60 bps***	***20.3%***	***69 bps***
One time expense on account of derecognition of lease receivable	-43	-	-	-	-
EBITDA (before Forex and Other Income)	**1,881**	**1,603**	**17.3%**	**1,801**	**4.4%**
Fx Gain/(Loss)	53	0	n/a	-48	n/a
Finance Cost	-102	-98	4.0%	-98	3.5%
Depreciation	-487	-406	20.0%	-479	1.7%
Other Income	212	105	n/a	117	80.8%
Exceptional items	-40	0	n/a	0	n/a
PBT before share of profit / (loss) of JV	**1,517**	**1,205**	**25.9%**	**1,293**	**17.3%**
Tax	-483	-383	26.3%	-370	30.6%
Share of Profit/(Loss) of JV	-2	2	n/a	-2	-37.0%
Profit after Tax	**1,032**	**824**	**25.2%**	**921**	**12.1%**
Minority Interest	1	1	-2.8%	0	26.2%
Net Profit attributable to Owners of the Company	**1,033**	**825**	**25.2%**	**921**	**12.1%**
Reported EPS	**17.86**	**14.20**	**25.8%**	**15.86**	**12.6%**
Average Fx rate US$1 = INR	**94.53**	**85.54**		**91.47**	

Debt Profile

Gross Debt (US$ Mn)



Net Debt Movement (US$ Mn)

Particulars	Q1FY27
Cash Flow from Business after Working Capital & Others	138
Less: Capex Normal/ANDA	-40
Free Cash Flow from Business	**98**
Less: Capex for acquisition of Lannett	-247
Less: Buyback	-85
Less: Capex for New business / product development	-20
Less: Capex for Biosimilars / Biologics CMO	-19
Add: Redemption of investments	75
Net Cash Flow after Buyback and Capex	**-197**

Debt as on (INR Cr)	Mar-23	Mar-24	Mar-25	Mar-26	Jun-26
Closing Rate (INR/USD)	82.170	83.405	85.475	94.835	94.663
Fx Loan restated in INR	4,638	3,994	5,883	6,709	7,472
Rupee Loan	224	2,324	2,065	964	922
Gross Debt	**4,862**	**6,318**	**7,948**	**7,673**	**8,393**
Cash Balance & Investments	6,453	6,467	8,307	10,676	8,790
Net Debt/(Net Cash)	**(1,591)**	**(149)**	**(359)**	**(3,002)**	**(397)**
Net Debt/(Net Cash) (US$ Mn)	(194)	(18)	(42)	(317)	(42)
Finance Cost#	4.0%	5.1%	5.5%	5.0%	4.8%
Income on Investments in INR (cumulative for the period)	148.5	288.3	356.4	331.3	81.4

Value (US$ Mn)	Q1FY27
Opening Cash / (Debt)	228
Free Cash Flow after Dividend	-197
Closing Cash / (Debt)	31
Investments	11
Closing Net Cash / (Debt) including Investments	**42**

Excluding interest on lease liabilities | Fx Debt and Fx Cash Balance are restated

Update on Biosimilars and Biologics Contract Manufacturing

CuraTeQ Biologics - Q1 FY27 Highlights

Continued execution across filings, market launches, and distribution alliances

Regulatory & Filings

- **ANVISA GMP certification secured:** Successfully completed the ANVISA inspection, securing GMP certification for both Drug Substance and Drug Product facilities and supporting future filings in LATAM
- **Denosumab filed with CHMP/EMA:** Filed both FILVIZY (biosimilar to Prolia) and FUGEVY (biosimilar to Xgeva), positioning us to address both the osteoporosis and oncology-supportive-care segments
- **Omalizumab filing on track for Q3:** EMA filing remains on schedule, keeping our respiratory franchise on track to become our third approved segment alongside oncology and bone health.
- **First U.S. FDA filings imminent:** Actively engaging with the FDA ahead of our U.S. filings this year — Omalizumab, Denosumab and Bevacizumab — marking CuraTeQ's entry into the world's largest biosimilars market

Commercial Expansion

- **UK — Full portfolio live:** All four MHRA-approved products — Bevqolva, Dazublys, Zefylti and Dyrupeg — are now supplying commercially.
- **Europe — Multi-country rollout underway:** Dazublys, Zefylti and Dyrupeg supplies are live across France, Germany, Portugal, Finland, Hungary, Lithuania and Latvia, with additional country launches already lined up to extend coverage further across the region.
- **LATAM —** Entry secured via Mexico: Bevqolva, Zefylti and Dyrupeg supplies have been initiated in Mexico, establishing our first commercial foothold in Latin America.

Partnerships to Scale

- **Expanded distribution reach across Europe:** Distribution agreements with STADA (EU) and Orion (Nordics) to give us scaled commercial coverage in the EU
- **First footprint in North Africa and CIS:** A strategic partnership secured in Algeria covers four products, marking our entry into the North African market and establishing a template for similar partner-led launches in other growth geographies. First approval secured in Uzbekistan with a strategic partner, marking our entry into CIS region.
- **Building a repeatable growth-market playbook:** Additional partnerships are being negotiated in new growth markets.

Capacity Expansion & Portfolio Broadening

Building the manufacturing base and pipeline depth to sustain growth into 2030

 **Bioreactor Capacity Addition**	10,000 L (4 × 2,500 L) mammalian cell-culture bioreactors, with integrated purification suites, being added to existing capacity at CuraTeQ.
 **AuroVaccines Merger**	Merger of AuroVaccines into CuraTeQ — repurposing vaccine capacity for biosimilars expansion — remains on track. Merger targeted for completion by March 2027.
 **Trastuzumab Portfolio Extension**	Trastuzumab 600 mg subcutaneous (SC) presentation on track to enter clinical studies in 2026 — broadening the oncology franchise beyond IV formulations with SC presentations.
 **New Device Modalities**	CuraTeQ is investing in new modalities — subcutaneous (SC) formulations and device-combination products such as auto-injectors and pens — positioning for the global healthcare shift from hospital-administered IV treatments to convenient, self-administered care at home.
 **Growth Market Expansion**	Continued build-out into growth markets in parallel with EU/UK supply ramp-up. Filings in LATAM, South Africa, SEA territories

CuraTeQ's Biosimilars Pipeline Status

Assets spanning oncology, respiratory, autoimmune and ophthalmology segments

Brand / Code	Molecule	Segment	Stage	Status Detail
DYRUPEG	Pegfilgrastim	Oncology	Launched	EMA, MHRA, HC approved & commercial
ZEFYLTI	Filgrastim	Oncology	Launched	EMA, MHRA approved & commercial
BEVQOLVA	Bevacizumab	Oncology	Launched	MHRA, HC, CDSCO approved; Phase 3 ongoing (additional markets) & commercial
DAZUBLYS	Trastuzumab	Oncology	Launched	EMA, MHRA, CDSCO approved & commercial
FUGEVY# / FILVIZY*	Denosumab	Bone Health	Filed	Filed with EMA, CDSCO; under review
OMAZIJEV	Omalizumab	Respiratory	To Be Filed	Phase 3 successful; EMA filing in Q3 2026
BP08	Tocilizumab	Autoimmune	Pivotal complete	Pivotal study complete. Filing in 2027
BP05	Ranibizumab	Ophthalmology	Phase 3	Phase 3 study in progress — recruiting last few patients
BP58	Trastuzumab S.C.	Oncology	Preclinical/Ph1	On track for Phase 1 study this FY
BP27	Undisclosed	—	Preclinical	Preclinical development complete
BP25	Undisclosed	—	Early Dev.	Preclinical development complete

*# FUGEVY is for an orthopedic indication (Fugevy™) And *FILVIZY is for an oncology indication (FILVIZY™)*

Key Next-Wave Products to Sustain Momentum

Large addressable markets underpin the post-2026 growth pipeline

Code	Key Indications	'25 Rev.	'30 Opp.
BP31	Plaque Psoriasis, PsA, Ankylosing Spondylitis	$6.7B	**$9.5B**
BP36	Atopic Dermatitis, Asthma	$13.1B	**$22B**
BP30	Multiple Myeloma	$14.4B	**$16B**
BP45	Ulcerative Colitis, Crohn's, Plaque Psoriasis, PsA	$17.6B	**$20B**
BP51	Ulcerative Colitis, Crohn's, Plaque Psoriasis, PsA	$4.2B	**$5.8B**
BP29	Multiple Sclerosis	$7.2B	**$6.5B**
BP41	Lung Cancer (NSCLC, ES-SCLC), HCC, Melanoma	$4.4B	**$8B**
BP50	Lung Cancer (NSCLC, ES-SCLC), Endometrial, Bladder Cancer	$5.9B	**$8B**

**Market sizing cited from various third-party market research reports*

TheraNym — Our Foray into Biologics Contract Manufacturing

Anchored by a long-term partnership with Merck Sharp & Dohme (MSD)

Unit 1 — Inaugurated

Inaugurated on 3 June 2026. On track to begin qualification activities in November 2026, ahead of first commercial revenues.

Unit 2 — Greenfield Build

As part of the third product schedule with MSD, ground-breaking completed for a greenfield Drug Substance facility. Full-scale construction begins October 2026, pending clearances.

Capacity

Unit 2 will add an aggregate 60 kL of mammalian cell-culture bioreactor capacity, plus requisite downstream purification infrastructure.

Capital Expenditure

Unit 2 is estimated at USD 180 Mn in capex, targeted to be ready for qualification in 2030.

The 2030 Vision

With Unit 1 and Unit 2's large-scale capacity and the MSD partnership, TheraNym is positioned to become a reliable node in the global biologics supply chain for life-saving therapies by 2030.

Outsourcing Growth — Expanding Market

The global biologics CDMO/CMO market is growing at a CAGR of over 12%. TheraNym represents Aurobindo's strategic foray into biologics contract manufacturing, as sponsors increasingly outsource complex biologics manufacturing to meet global demand.

>12% CAGR — Global Biologics CDMO/CMO Market

Filings Snapshot

US ANDA Filings Snapshot as on 30th June 2026

ANDA Filings



Unit wise ANDA Fillings

Site	Details	Final Approval	Tentative Approval*	Under Review	Total
Unit III	Oral Formulations	123	6	5	134
Unit VIB	Cephalosporin Orals	15	0	0	15
Unit VII (SEZ)	Oral Formulations	165	5	6	176
Unit XII	Penicillin Orals & Injectables	12	0	1	13
APL HC I	Oral Formulations	30	3	11	44
APL HC III	Orals & Topicals	17	0	9	26
APL HC IV	Oral Formulations	100	11	20	131
Aurolife & Aurolife – II	Orals & Topicals	30	0	13	43
Eugia I	Oral & Injectable Formulations	43	7	11	61
Eugia II	Penem Injectables	2	0	1	3
Eugia III	Injectables & Ophthalmics	108	1	40	149
Eugia SEZ	Injectables	11	0	0	11
Eugia Steriles	Injectables	3 (2^)	0	3(1^)	6
Aurovitas	Oral Formulations	0	0	3	3
Others**		78	0	3	81
Total		**737**	**33**	**126**	**896**

*Tentative Approvals (TAs) include 6 ANDAs approved under PEPFAR
^ Represents dual filing from Eugia 3 and Eugia 5

**Including acquired ANDAs from Mylan

Therapy	ANDAs	Addressable Market Size (US$ Bn)^^
CNS	166	35.0
ARV	30	1.5
CVS	125	44.7
SSP & Cephs	35	0.7
Anti-Diabetic	27	34.6
Oncology & Hormones	65	18.6
Gastroenterological	50	5.5
Controlled Substances	16	1.0
Respiratory (incl. Nasal)	22	1.7
Ophthalmic	19	4.1
Dermatology	20	1.3
Penem Injectables	3	0.2
Others	318	33.5
Total	**896**	**182.3**

^^Source: IQVIA MAT Jun'26

Thank You

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.08.05 19:53:48 +05'30'

AUROBINDO
Committed to healthier life!

For more information, contact:
Investor Relations | Corporate Communications
+91 40 6672 1211

ir@aurobindo.com

www.aurobindo.com